Myonexus Therapeutics receives FDA orphan drug designation for LGMD type 2E treatment

(CincyTech) Myonexus Therapeutics , a clinical-stage gene therapy company developing first ever corrective gene therapies for limb girdle muscular dystrophies, and Nationwide Children's Hospital announce the US Food and Drug Administration (FDA) has granted Orphan Drug designation to Myonexus' lead candidate, MYO-101 for the treatment of limb girdle muscular dystrophy (LGMD) type 2E.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news